Ustekinumab plus dupilumab in the treatment of concomitant psoriasis and prurigo nodularis

Kabbani, Mariam; Mpita, Greta Mboyo; Benhadou, Farida

doi:10.1111/jdv.18445

Cited by 3 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The other 13 articles were excluded when they were further studied, leaving behind only 24 articles that fulfilled the selection criteria and were included in the study (Figure 1). The 24 publications included only 1 prospective study (11), 5 retrospective studies (12-16), 5 case series (17-21), and 13 case reports (22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34).…”

Section: Statistical Analysesmentioning

confidence: 99%

Dupilumab for the treatment of prurigo nodularis: A systematic review

Cao

Jiang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundConventional treatment techniques have limited efficacy and more side effects in the treatment of prurigo nodularis. The better alternative treatment option for better outcomes of the disease is dupilumab.ObjectiveThe objective of this study was to systematically review dupilumab-related treatment outcomes in prurigo nodularis.MethodsSeveral databases like Embase, PubMed, Web of Science, and Cochrane library were searched for data acquisition on October 8, 2022. Based on Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, 24 publications were included in this study.ResultsAfter 4,12,16 and more than 16 weeks of dupilumab treatment, 8.3% (n=5/60), 34.4% (n=11/32), 3.6% (n=2/56), and 45.3% (n=29/64) of patients had complete remission, respectively. In addition, 85.0% (n=51/60), 59.4% (n=19/32), 83.9% (n=47/56), and 43.8% (n=28/64) had partial remission, respectively. Moreover, 6.7% (n=4/60), 6.3% (n=2/32), 12.5% (n=7/56), and 10.9% (n=7/64) showed no remission, respectively, and significant reduction of numeric rating scale itch intensity (from 9.0 to 4.9, 2.1, 2.8, 0.9) was attained. There were no serious adverse events observed during treatment, but the most common event observed was conjunctivitis (12.6%, n=15/119).ConclusionsDupilumab has definite effectiveness and safety in prurigo nodularis treatment.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO, identifier (CRD42022365802).

show abstract

Section: Statistical Analysesmentioning

confidence: 99%

Dupilumab for the treatment of prurigo nodularis: A systematic review

Cao

Jiang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Adalimumab/azathioprine/methotrexate

2023

Reactions Weekly

View full text Add to dashboard Cite

Combination treatment with monoclonal antibodies for the management of severe asthma and immune-mediated inflammatory diseases: a comprehensive review

Carriera,

Caporuscio,

Fantò

et al. 2024

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

Biological drugs have revolutionized the management of severe asthma, and a tailored treatment approach made it possible to consider remission as an achievable treatment target. The incidence of autoimmune diseases is increasing in many parts of the world. Patients suffering from severe asthma, eligible or already treated with an asthma-approved biologic agent, may suffer from another immune-mediated inflammatory disease (IMID) that could require the simultaneous use of a second monoclonal antibody. The real-life studies available in the literature describing the concurrent administration of an asthma-approved biologic agent with another biologic for a different immune disease, obtained through a systematic search on online databases based on monoclonal antibodies, were collected and analyzed. 26 articles were included in this review according to the prespecified inclusion and exclusion criteria. All included papers were retrospective in nature. Study designs were case reports (n=18), case series (n=3), retrospective chart reviews (n=3), retrospective observational studies (n=1), and cohort studies (n=1). The study is intended to present, within the current literature, all the administered combinations of severe asthma-approved biologics with monoclonal antibodies for a different indication. Those were grouped according to the IMID for whom the second biologic agent, with a different mechanism of action, was prescribed. The combinations prescribed to the cohort of patients specifically treating uncontrolled severe asthma were deeper evaluated in the discussion section, since an analysis of these therapeutic combinations deriving from real-life experiences may be useful to optimize the management of patients with severe asthma, ultimately leading to improved patient care and outcomes. Prospective registries and future studies are required to assess the safety and efficacy of combination therapies for severe asthmatic patients who suffer from an IMID.

show abstract

Ustekinumab plus dupilumab in the treatment of concomitant psoriasis and prurigo nodularis

Cited by 3 publications

References 11 publications

Dupilumab for the treatment of prurigo nodularis: A systematic review

Dupilumab for the treatment of prurigo nodularis: A systematic review

Adalimumab/azathioprine/methotrexate

Combination treatment with monoclonal antibodies for the management of severe asthma and immune-mediated inflammatory diseases: a comprehensive review

Contact Info

Product

Resources

About